Telomir Pharmaceuticals (NASDAQ:TELO) Shares Down 4.2% – Should You Sell?

Telomir Pharmaceuticals, Inc. (NASDAQ:TELO)’s share price was down 4.2% during mid-day trading on Thursday . The stock traded as low as $1.12 and last traded at $1.13. Approximately 67,907 shares traded hands during mid-day trading, a decline of 49% from the average daily volume of 132,274 shares. The stock had previously closed at $1.18.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on TELO shares. Weiss Ratings reissued a “sell (e+)” rating on shares of Telomir Pharmaceuticals in a research note on Thursday, January 22nd. Rodman & Renshaw started coverage on Telomir Pharmaceuticals in a research report on Tuesday, January 13th. They issued a “buy” rating for the company. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $15.00.

Telomir Pharmaceuticals Stock Down 4.2%

The firm has a market cap of $38.85 million, a price-to-earnings ratio of -3.05 and a beta of -0.49. The company has a 50-day moving average price of $1.30 and a 200 day moving average price of $1.40.

Institutional Trading of Telomir Pharmaceuticals

Hedge funds have recently made changes to their positions in the stock. Marshall Wace LLP purchased a new position in Telomir Pharmaceuticals during the second quarter valued at approximately $95,000. Raymond James Financial Inc. grew its holdings in shares of Telomir Pharmaceuticals by 4,101.9% during the 3rd quarter. Raymond James Financial Inc. now owns 75,340 shares of the company’s stock valued at $105,000 after acquiring an additional 73,547 shares in the last quarter. Y Intercept Hong Kong Ltd acquired a new position in shares of Telomir Pharmaceuticals in the second quarter worth $81,000. Jane Street Group LLC acquired a new position in shares of Telomir Pharmaceuticals in the second quarter worth $62,000. Finally, XTX Topco Ltd purchased a new stake in shares of Telomir Pharmaceuticals during the fourth quarter worth $53,000.

About Telomir Pharmaceuticals

Telomir Pharmaceuticals, Inc (NASDAQ: TELO) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel small-molecule therapies for cardiometabolic and fibrotic diseases. Leveraging a proprietary target discovery platform, the company aims to identify and modulate key biological pathways implicated in tissue fibrosis, inflammation and metabolic dysregulation. Its research strategy centers on oral agents intended to address high-unmet-need conditions such as nonalcoholic steatohepatitis (NASH) and systemic fibrotic disorders, where existing treatment options are limited.

The company’s lead development candidate is an oral inhibitor currently in early-phase clinical trials that targets growth factors involved in fibrotic tissue remodeling.